General Information of Drug (ID: DM1LMFG)

Drug Name
FAUC213 Drug Info
Synonyms
FAUC 213; 337972-47-1; FAUC-213; UNII-G8F040299R; CHEMBL310843; G8F040299R; 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine; GTPL974; CTK8E8281; DTXSID40187460; HMS3263F09; Tox21_501144; BDBM50102712; ZINC52541476; MFCD06798338; Pyrazolo(1,5-a)pyridine, 2-((4-(4-chlorophenyl)-1-piperazinyl)methyl)-; CCG-222448; LP01144; API0002679; NCGC00261829-01; NCGC00165795-01; NCGC00165795-02; RT-012699; FAUC 213, > J-019326; 2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-pyrazolo[1,5-a]pyridine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10336538
CAS Number
CAS 337972-47-1
TTD Drug ID
DM1LMFG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Drug(s) Targeting Dopamine D4 receptor (D4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [3]
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [4]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [5]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [6]
L-745,870 DMTGR25 Psychotic disorder 6A20-6A25 Phase 2 [7]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [8]
ABT-724 DMDQVY4 Erectile dysfunction HA01.1 Discontinued in Phase 2 [9]
Lu-35138 DMQ7A35 Psychotic disorder 6A20-6A25 Discontinued in Phase 2 [10]
NGD-94-4 DMZ9WLO Schizophrenia 6A20 Discontinued in Phase 1 [11]
PD-165167 DMD0GB4 Schizophrenia 6A20 Preclinical [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D4 receptor (D4R) TTE0A2F DRD4_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 974).
2 Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
8 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
9 Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
11 I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.